| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2003;41:1035.)
© 2003 American Heart Association, Inc.
Scientific Contribution |
From the Cardiovascular Division, Department of Pathophysiology, Nagoya University Graduate School of Medicine (H.I., M.Y.), Nagoya; Department of Gene Therapy, Gifu International Institute of Biotechnology (Y.Y., M.T.), Mitake; and the Cardiovascular Center, Nagoya Daini Red Cross Hospital (T.O., H.H.), Nagoya, Japan.
Correspondence to Yoshiji Yamada, MD, PhD, FAHA, Department of Gene Therapy, Gifu International Institute of Biotechnology, Yagi Memorial Park, 2193-128 Mitake, Gifu 505-0116, Japan. E-mail yoyamada{at}giib.or.jp
| Abstract |
|---|
|
|
|---|
T in the G protein ß3 subunit gene and 190G
A in the CC chemokine receptor 2 gene) were significantly associated with hypertension in men and that one polymorphism (-238G
A in the tumor necrosis factor
gene) was significantly associated with hypertension in women. These results suggest that 2 and 1 genes may be susceptibility loci for hypertension in Japanese men and women, respectively, and that genotyping of these polymorphisms may prove informative for prediction of the genetic risk for hypertension.
Key Words: hypertension, essential hypertension, genetic blood pressure genetics polymorphism population risk factors
| Introduction |
|---|
|
|
|---|
-adducin,6 the ß3 subunit of G proteins,7 and the ß2-adrenergic receptor,8 increase the risk of hypertension, the genes that contribute to genetic susceptibility to this condition remain to be identified definitively. In addition, because of ethnic divergence of gene polymorphisms, it is important to construct a database of polymorphisms related to hypertension in each ethnic group. We have now performed a large-scale association study for 33 single nucleotide polymorphisms (SNPs) of 27 candidate genes and hypertension. Our aim was to predict the genetic risk for hypertension and thereby to contribute to the primary prevention of this condition.
| Methods |
|---|
|
|
|---|
140 mm Hg or diastolic BP of
90 mm Hg, or both) or had taken antihypertensive drugs. Individuals with CAD, valvular heart disease, congenital malformations of the heart or vessels, or renal or endocrinologic diseases that cause secondary hypertension were excluded from the study. The 873 control subjects (533 men, 340 women) with normal BP (systolic BP of <140 mm Hg and diastolic BP of <90 mm Hg) were recruited from individuals who were found to have at least one of the conventional risk factors for CAD, including habitual cigarette smoking (
10 cigarettes daily), obesity (body mass index [BMI] of
26 kg/m2), diabetes mellitus (fasting blood glucose of
6.93 mmol/L or hemoglobin A1c of
6.5%, or both), hypercholesterolemia (serum total cholesterol of
5.72 mmol/L), and hyperuricemia (serum uric acid of
0.46 mmol/L for men or
0.33 mmol/L for women), but who had no history of CAD. Most of the subjects with hypertension and controls in the present study were included in the control group of our previous study.9 BP was measured with subjects in the seated position according to the guidelines of the American Heart Association.10 The study protocol was approved by the Committees on the Ethics of Human Research of Nagoya University Graduate School of Medicine, Gifu International Institute of Biotechnology, and Nagoya Daini Red Cross Hospital, and informed consent was obtained from each participant.
Selection of Candidate Gene Polymorphisms
With the use of public databases, including PubMed and Online Mendelian Inheritance in Man, we selected 27 candidate genes that have been characterized and were suggested to be associated with hypertension on the basis of a comprehensive overview of vascular biology, platelet and leukocyte biology, coagulation and fibrinolysis cascades, as well as lipid and glucose metabolism and other metabolic factors. We further selected 33 SNPs of these genesmost located in the promoter region, exons, or splice donor or acceptor sites in intronsthat might be expected to affect the function or expression of the encoded protein (Table 1).9 We examined the relation of these SNPs to hypertension in the 1940 participants of the present study.
|
Genotyping of SNPs
Venous blood (7 mL) was collected from each subject in tubes containing 50 mmol/L EDTA (disodium salt), and genomic DNA was isolated with a kit (Qiagen). Genotypes of SNPs were determined with a fluorescence- or colorimetry-based allele-specific DNA primer-probe assay system (Toyobo Gene Analysis) (Appendix 2) as previously described.9
Statistical Analysis
Quantitative clinical data were compared between patients with hypertension and controls by the unpaired Student t test or the Mann-Whitney U test. Qualitative data were compared by the
2 test. Allele frequencies were estimated by the gene-counting method, and the
2 test was used to identify significant departures from Hardy-Weinberg equilibrium. We performed multivariate logistic regression analysis to adjust risk factors, with hypertension as a dependent variable and independent variables including age, BMI, smoking status (0=nonsmoker, 1=smoker), metabolic variables (0=no history of diabetes mellitus, hypercholesterolemia, or hyperuricemia; 1=positive history), and genotype of each SNP. Each genotype was assessed according to dominant, recessive, and additive genetic models, and the P value, odds ratio, and 95% confidence interval were calculated. Unless indicated otherwise, a P value <0.05 was considered statistically significant.
| Results |
|---|
|
|
|---|
|
Multivariate logistic regression analysis with adjustment for age, BMI, and the prevalence of smoking, diabetes mellitus, hypercholesterolemia, and hyperuricemia revealed that 2 different sets of 4 of the 33 SNPs examined were associated with hypertension in men and women on the basis of a probability value <0.05 in either a dominant, recessive, or additive genetic model. However, given the multiple comparisons of genotypes, we considered a probability value <0.01 to be statistically significant for such associations. On the basis of this criterion, the 825C
T SNP of the G protein ß3 subunit gene and the 190G
A SNP of the CC chemokine receptor 2 gene were significantly associated with hypertension in men, and the -238G
A SNP of the tumor necrosis factor
gene was significantly associated with hypertension in women (Table 3). The chromosomal loci of the corresponding genes are also shown in Table 3. The -850C
T and -238G
A SNPs of the tumor necrosis factor
gene related to hypertension in women were not in linkage disequilibrium (pairwise linkage disequilibrium coefficient, D[D/Dmax], of -0.310 and standardized linkage disequilibrium coefficient, r=-0.020; P= 0.613,
2 test). The genotype distributions of the various SNPs related to hypertension are shown in Table 4.
|
|
| Discussion |
|---|
|
|
|---|
Many association studies have previously examined the relations between gene polymorphisms and hypertension. The results of most of these studies, however, remain controversial, with no consensus on their implications, mainly because of the limited population size of the studies, the ethnic diversity of gene polymorphisms, and complicating environmental factors. Furthermore, even though associations have been detected, the relative risk (odds ratio) conferred by a single polymorphism has tended to be low in large populations. The regulation of BP involves both the integration of a variety of biological systems that control the structure and tone of the vasculature and the volume and composition of body fluid, as well as the adaptation of these systems to constantly changing physiological needs.11 The 33 SNPs of the 27 genes examined in the present study were selected on the basis of a comprehensive overview of vascular biology, platelet and leukocyte biology, the fibrinolysis system, as well as lipid and glucose metabolism and other metabolic factors. Although these genes were studied in relation to myocardial infarction in our previous study,9 they are also candidates for susceptibility loci to hypertension. The genes now shown to be associated with hypertension may play important roles in vascular smooth muscle cell biology (G protein ß3 subunit), vascular inflammation (tumor necrosis factor
), and monocyte and lymphocyte biology (CC chemokine receptor 2). Given that 3 SNPs were located on different chromosomes, these SNPs were not in linkage disequilibrium.
For men, the 825C
T SNP of the G protein ß3 subunit gene and the 190G
A SNP of the CC chemokine receptor 2 gene were significantly associated with hypertension. Siffert et al7 previously showed that the 825C
T SNP in exon 10 of the G protein ß3 subunit gene was associated with hypertension. The T allele was associated with the appearance of a splice variant lacking nucleotides 498 to 620 in exon 9 of the primary transcript, resulting in the loss of 41 amino acids (including one WD repeat domain) in the encoded protein. This splice variant may be responsible for the enhanced signal transduction via pertussis toxinsensitive G proteins previously observed in lymphoblasts and fibroblasts from certain individuals with essential hypertension.12,13 Our present results indicate that the T allele of the 825C
T SNP is a risk factor for hypertension in men, consistent with the observation of Siffert et al.7 However, the allele frequency of this SNP in the Japanese population of the present study (C allele, 54%; T allele, 46%) is significantly different (P<0.0001,
2 test) from that in the German population of the previous study7 (C allele, 75%; T allele, 25%), suggesting that the allele frequency differs among ethnic groups.
CC chemokine receptor 2 is a receptor for monocyte chemoattractant protein (MCP)-1 and closely related proteins including MCP-2, -3, -4, and -5. MCP-1 is chemotactic for monocytes and other leukocyte subsets. Both MCP-1 and CC chemokine receptor 2 have been implicated in the development of CAD.14 The A allele of the 190G
A (Val64Ile) SNP of the CC chemokine receptor 2 gene was previously suggested to be associated with a reduced risk for severe CAD,15 whereas another study showed a lack of association between this SNP and the prevalence of myocardial infarction.16 CC chemokine receptor 2 has also been shown to contribute to the development of hypertension,17 although the 190G
A SNP of the corresponding gene has not previously been associated with this condition. Our results suggest that the A allele of the 190G
A SNP of this gene is a risk factor for predisposition to hypertension in men.
For women, the -238G
A SNP of the tumor necrosis factor
gene was significantly associated with the prevalence of hypertension. The tumor necrosis factor
gene locus was previously shown to be associated with obesity-related hypertension in French Canadians.18 A -308A
G SNP of the tumor necrosis factor
gene also previously showed a tendency to associate with essential hypertension, although statistical significance was not achieved.19 The serum concentration of this cytokine was associated with systolic BP and insulin resistance in a native Canadian population.20 Tumor necrosis factor
stimulates the production of the potent vasoconstrictor endothelin-1 by cultured vascular endothelial cells,21 and the serum concentrations of these 2 agents were positively correlated in subjects with android-type obesity.22 These previous observations, as well as our present results, suggest that the tumor necrosis factor
gene is a candidate locus for susceptibility to hypertension and that the A allele of the -238G
A SNP of this gene protects against the development of hypertension, although the frequency of the A allele was low in women (G and A alleles, 96.8% and 3.2%, respectively, in controls, and 98.6% and 1.4%, respectively, in subjects with hypertension).
The 33 SNPs examined in the present study likely represent only a small proportion of polymorphisms potentially associated with hypertension. Thus, it remains possible that further investigations will identify other polymorphisms that are associated with this condition. It is also possible that one or more of the SNPs associated with hypertension in our study are in linkage disequilibrium with polymorphisms of other nearby genes that are actually responsible for the development of hypertension. Our present results suggest, however, that the genes encoding the G protein ß3 subunit and CC chemokine receptor 2 are susceptibility loci for hypertension in Japanese men and that the tumor necrosis factor
gene constitutes such a locus in Japanese women. Genotyping of these polymorphisms may prove informative for prediction of the genetic risk for hypertension and thereby may contribute to the primary prevention of hypertension and of cardiovascular, cerebral, or renal diseases induced by this condition.
Perspectives
We have examined the relation of hypertension to 33 SNPs of 27 candidate genes in a large-scale association study with 1940 individuals and identified 2 SNPs (825C
T in the G protein ß3 subunit gene and 190G
A in the CC chemokine receptor 2 gene) in men and 1 SNP (-238G
A in the tumor necrosis factor
gene) in women that were significantly associated with hypertension. These results suggest that 2 and 1 genes may be susceptibility loci for hypertension in Japanese men and women, respectively. Genotyping of these SNPs may prove informative for prediction of the genetic risk for hypertension.
| Appendix 1 |
|---|
|
|
|---|
| Appendix 2 |
|---|
|
|
|---|
|
| Acknowledgments |
|---|
Received December 18, 2002; first decision January 15, 2003; accepted February 27, 2003.
| References |
|---|
|
|
|---|
2. Xu X, Rogus JJ, Terwedow HA, Yang J, Wang Z, Chen C, Niu T, Wang B, Xu H, Weiss S, Schork NJ, Fang Z. An extreme-sib-pair genome scan for genes regulating blood pressure. Am J Hum Genet. 1999; 64: 16941701.[CrossRef][Medline] [Order article via Infotrieve]
3. Krushkal J, Ferrell R, Mockrin SC, Turner ST, Sing CF, Boerwinkle E. Genome-wide linkage analysis of systolic blood pressure using highly discordant siblings. Circulation. 1999; 99: 14071410.
4. Rice T, Rankinen T, Province MA, Chagnon YC, Pérusse L, Borecki IB, Bouchard C, Rao DC. Genome-wide linkage analysis of systolic and diastolic blood pressure: the Québec Family Study. Circulation. 2000; 102: 19561963.
5. Jeunemaitre X, Soubrier F, Kotelevtsev YV, Lifton RP, Williams CS, Charru A, Hunt SC, Hopkins PN, Williams RR, Lalouel J-M, Corvol P. Molecular basis of human hypertension: role of angiotensinogen. Cell. 1992; 71: 169180.[CrossRef][Medline] [Order article via Infotrieve]
6. Cusi D, Barlassina C, Azzani T, Casari G, Citterio L, Devoto M, Gloriso N, Lanzani C, Manunta P, Righetti M, Rivera R, Stella P, Troffa C, Zagato L, Bianchi G. Polymorphisms of
-adducin and salt sensitivity in patients with essential hypertension. Lancet. 1997; 349: 13531357.[CrossRef][Medline]
[Order article via Infotrieve]
7. Siffert W, Rosskop D, Siffert G, Busch S, Moritz A, Erbel R, Sharma AM, Ritz E, Wichmann H-E, Jakobs KH, Horsthemke B. Association of a human G-protein ß3 subunit variant with hypertension. Nat Genet. 1998; 18: 4548.[CrossRef][Medline] [Order article via Infotrieve]
8. Bray MS, Krushkal J, Li L, Ferrell R, Kardia S, Sing CF, Turner ST, Boerwinkle E. Positional genomic analysis identifies the ß2-adrenergic receptor gene as a susceptibility locus for hypertension. Circulation. 2000; 101: 28772882.
9. Yamada Y, Izawa H, Ichihara S, Takatsu F, Ishihara H, Hirayama H, Sone T, Tanaka M, Yokota M. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med. 2002; 347: 19161923.
10. Perloff D, Grim C, Flack J, Frohlich ED, Hill M, McDonald M, Morgenstern BZ. Human blood pressure determination by sphygmomanometry. Circulation. 1993; 88: 24602470.
11. Lalouel J-M, Rohrwasser A. Development of genetic hypotheses in essential hypertension. J Hum Genet. 2001; 46: 299306.[CrossRef][Medline] [Order article via Infotrieve]
12. Siffert W, Rosskopf D, Moritz A, Wieland T, Kaldenberg-Stasch S, Kettler N, Hartung K, Beckmann S, Jakobs KH. Enhanced G protein activation in immortalized lymphoblasts from patients with essential hypertension. J Clin Invest. 1995; 96: 759766.[Medline] [Order article via Infotrieve]
13. Pietruck F, Moritz A, Montemurro M, Sell A, Busch S, Rosskopf D, Virchow S, Esche H, Brockmeyer N, Jakobs KH, Siffert W. Selectively enhanced cellular signaling by Gi proteins in essential hypertension. G
i2, G
i3, Gß1, and Gß2 are not mutated. Circ Res. 1996; 79: 974983.
14. Ylä-Herttuala S, Lipton BA, Rosenfeld ME, Särkioja T, Yoshimura T, Leonard EJ, Witztum JL, Steinberg D. Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci U S A. 1991; 88: 52525256.
15. Szalai C, Duba J, Prohaszka Z, Kalina A, Szabo T, Nagy B, Horvath L, Csaszar A. Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-12518 G/G genotype in CAD patients. Atherosclerosis. 2001; 158: 233239.[CrossRef][Medline] [Order article via Infotrieve]
16. Gonzalez P, Alvarez R, Batalla A, Reguero JR, Alvarez V, Astudillo A, Cubero GI, Cortina A, Coto E. Genetic variation at the chemokine receptors CCR5/CCR2 in myocardial infarction. Genes Immun. 2001; 2: 191195.[CrossRef][Medline] [Order article via Infotrieve]
17. Bush E, Maeda N, Kuziel WA, Dawson TC, Wilcox JN, DeLeon H, Taylor WR. CC chemokine receptor 2 is required for macrophage infiltration and vascular hypertrophy in angiotensin II-induced hypertension. Hypertension. 2000; 36: 360363.
18. Pausova Z, Deslauriers B, Gaudet D, Tremblay J, Kotchen TA, Larochelle P, Cowley AW, Hamet P. Role of tumor necrosis factor-
gene locus in obesity and obesity-associated hypertension in French Canadians. Hypertension. 2000; 36: 1419.
19. Frossard PM, Gupta A, Pravica V, Perry C, Hutchinson IV, Lukic ML. A study of five human cytokine genes in human essential hypertension. Mol Immunol. 2002; 38: 969976.[Medline] [Order article via Infotrieve]
20. Zinman B, Hanley AJG, Harris SB, Kwan J, Fantus IG. Circulating tumor necrosis factor-
concentrations in a native Canadian population with high rates of type 2 diabetes mellitus. J Clin Endocrinol Metab. 1999; 84: 272278.
21. Kahaleh MB, Fan PS. Effect of cytokines on the production of endothelin by endothelial cells. Clin Exp Rheumatol. 1997; 15: 163167.[Medline] [Order article via Infotrieve]
22. Winkler G, Lakatos P, Salamon F, Nagy Z, Speer G, Kovacs M, Harmos G, Dworak O, Cseh K. Elevated serum TNF-
level as a link between endothelial dysfunction and insulin resistance in normotensive obese patients. Diabetes Med. 1999; 16: 207211.[CrossRef][Medline]
[Order article via Infotrieve]
This article has been cited by other articles:
![]() |
E. Lavergne, J. Labreuche, M. Daoudi, P. Debre, F. Cambien, P. Deterre, P. Amarenco, C. Combadiere, and on Behalf of the GENIC Investigators Adverse Associations Between CX3CR1 Polymorphisms and Risk of Cardiovascular or Cerebrovascular Disease Arterioscler Thromb Vasc Biol, April 1, 2005; 25(4): 847 - 853. [Abstract] [Full Text] [PDF] |
||||
![]() |
Minerva BMJ, May 15, 2003; 326(7398): 1096 - 1096. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2003 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |